Clinical trials
Sexually Transmitted Infections (Not HIV or Hepatitis) clinical trials
Below are recruiting sexually transmitted infections (not hiv or hepatitis) clinical trials, each written for real people, not researchers. We’re tracking 794 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06395129Recruiting
Better syringes for people who inject drugs
This study provides safer, low-dead-space syringes to people who inject drugs to help reduce the spread of infections like HIV and hepatitis C. It is designed for people in low- and middle-income countries who use needle exchange programs.
YerevanAges 18 years+ - NCT06650852RecruitingPhase 2
A study of 3 drugs for chronic hepatitis B
This trial tests a combination of three drugs (BRII-179, BRII-835, and PEG-IFNα) to see if they can better control chronic hepatitis B. It is for people who are already on antiviral therapy and have well-controlled virus levels.
Beijing, Beijing MunicipalityAges 18–60 - NCT07200908RecruitingPhase 3
Comparing brelovitug and bulevirtide for hepatitis delta
This trial tests a new drug, brelovitug, against an existing one, bulevirtide, for people with chronic hepatitis delta. It aims to find a better treatment to lower the virus and protect the liver.
GrazAges 18–99 - NCT07240350Recruiting
Hepatitis B immune response in surgery patients
This study looks at how the body's immune system responds in people with chronic hepatitis B who also need surgery on certain organs. The goal is to learn more about the immune reaction in tonsils, lymph nodes, or other tissues to help find better treatments for hepatitis B.
Guangzhou, GuangdongAges 18–75 - NCT07487623Recruiting
Nutritional supplement for liver protection in hepatitis C
This trial tests whether a special nutritional supplement can protect the liver in people with chronic hepatitis C. If you have mild to moderate liver damage and meet the criteria, you may be able to join.
Guadalajara, JaliscoAges 18–69 - NCT07519330RecruitingPhase 2
Testing HH-006 treatment for chronic hepatitis B
This study tests a new drug called HH-006 to see if it can help treat chronic hepatitis B infection. Participants will be grouped by their infection level, and the study checks whether the drug is safe and works to reduce the hepatitis B virus.
Chongqing, Chongqing MunicipalityAges 18–45 - NCT06805656RecruitingPhase 2
Trial to reduce HIV reservoirs aiming for treatment-free remission
This study tests whether a combination approach, including a drug called nicotinamide (a form of vitamin B3) and other strategies, can reduce the hidden HIV reservoir enough to allow a temporary pause in antiretroviral therapy without the virus rebounding. It is for people who have well-controlled HIV and strong immune systems.
São Paulo, São PauloAges 18–65 - NCT04014413Recruiting
Fecal transplant for gut and immune-related conditions
This trial studies whether fecal microbiota transplantation (FMT)—a medical procedure using stool from a screened donor to restore gut bacteria—can improve safety and outcomes for people with certain bowel, immune, and metabolic conditions. It may help if your symptoms are thought to be related to an unhealthy gut microbiome, though eligibility is broad and depends on specific safety factors.
Hong Kong, ShatinAges Any age - NCT04851015RecruitingPhase 3
Low-dose TMP-SMX for Pneumocystis pneumonia (PCP)
This Phase 3 study tests whether low-dose trimethoprim-sulfamethoxazole (also called TMP-SMX) can treat Pneumocystis pneumonia (PCP) in people with weakened immune systems. It may help improve treatment while reducing side effects compared with standard dosing.
Montreal, QuebecAges 18–100 - NCT06966908Recruiting
Managing hepatitis B in non-specialty hospital settings
This study looks at how patients with chronic hepatitis B are managed when they visit non-liver clinics. It aims to improve care and may also include a survey about quality of life for those starting treatment.
Guangzhou, GuangdongAges Any age - NCT03135886Recruiting
Testing for HIV in opioid treatment programs
This project studies how to improve offering and completing HIV (and hepatitis C) tests in opioid treatment programs. It may help increase timely follow-up and linkage to care when results are positive.
New York, New YorkAges 18 years+ - NCT07481175RecruitingPhase 1
Testing a drug to reduce hidden HIV early after treatment start
This trial tests whether adding venetoclax, a drug that helps infected cells die, at the start of HIV treatment can lower the amount of hidden virus that stays in the body. It may help reduce the HIV reservoir.
AarhusAges 18–70 - NCT03449706Recruiting
Tracking immune changes in early HIV
This study looks closely at how your immune system and HIV infection markers change right after a new HIV diagnosis. It may help doctors understand the earliest stages of HIV and improve how infections are measured and followed over time.
Ghent, Oost-VlaanderenAges 18–65 - NCT04166266Recruiting
Study of adults with hepatitis D and hepatitis B coinfection
This study follows adults who have ongoing hepatitis D infection along with hepatitis B. It aims to better understand this mixed infection and how these patients do over time.
AngersAges 18 years+ - NCT04970836Recruiting
Hepatitis B revaccination for young adults in Taiwan
This study looks at how well your immune system responds after getting 1–2 extra doses of the hepatitis B vaccine. It may help doctors understand who needs revaccination and how to strengthen protection.
TaipeiAges 20–36 - NCT05856890RecruitingPhase 1
Test antibody treatment for chronic hepatitis B
This Phase 1 trial tests HepB mAb19, an antibody medicine, in adults with chronic hepatitis B. The goal is to see how it works and how safe it is in people whose hepatitis B is controlled on current antiviral treatment.
New York, New YorkAges 18–70 - NCT06023056Recruiting
Hepatitis B vaccine after newborn surgery
This trial tests whether giving the hepatitis B vaccine to full-term newborns who had multiple stomach or intestine surgeries is safe and works well. It aims to protect these babies from hepatitis B infection.
Chongqing, Chongqing MunicipalityAges Any age - NCT06126913Recruiting
Community HIV care for people newly diagnosed
This study tests whether getting HIV care through a community program is as helpful as going to a clinic for people who just found out they have HIV. It looks at how well they stay in care and take their medicine.
KampalaAges Any age - NCT06431945Recruiting
Hepatitis C testing for injection drug users
This trial offers free hepatitis C testing for people who inject or have injected drugs. The goal is to find hidden cases early so they can get treatment.
BrnoAges 18 years+ - NCT07079150Recruiting
Long-term pegylated interferon study for HBV families with poor outcomes
This study looks at how well pegylated interferon alpha-2b works over the long term for people with chronic hepatitis B who come from families where the virus has caused serious liver problems like cirrhosis or liver cancer. The goal is to see if this treatment can help prevent these bad outcomes in family members.
Xi'an, ShaanxiAges 18–70 - NCT00001281Recruiting
Understanding how HIV affects blood cells and body fluids
This research study examines how HIV works in the blood and body fluids of people with and without HIV. By studying blood samples, researchers hope to better understand HIV infection and develop better treatments.
Washington D.C., District of ColumbiaAges 18–120 - NCT07682961RecruitingPhase 3
Study of new HIV injection vs. standard injectables
This phase 3 trial tests a new long-acting, injectable two-drug combination (lenacapavir + teropavimab + zinlirvimab) vs. another injectable combo (cabotegravir + rilpivirine) for people whose HIV is already well-controlled on daily oral meds. It aims to see if the new combo can keep the virus under control with fewer injections.
San Francisco, CaliforniaAges 18 years+ - NCT07040319RecruitingPhase 1/Phase 2
Hepatitis C treatment study for pregnant women
This study tests a medicine called glecaprevir/pibrentasvir for pregnant women with hepatitis C, with or without HIV. It aims to see how the medicine works in the body and if it is safe during pregnancy.
Los Angeles, CaliforniaAges 16–45 - NCT07650916RecruitingPhase 3
A study of two ultra-long-acting HIV shots
This trial tests a new ultra-long-acting injectable combination of cabotegravir and rilpivirine for people with HIV who already have the virus under control. It aims to see if these shots can keep the virus suppressed with fewer doses.
Phoenix, ArizonaAges 12 years+
Hear when a new Sexually Transmitted Infections (Not HIV or Hepatitis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for sexually transmitted infections (not hiv or hepatitis)?
- Yes. Clin2 currently lists 794 recruiting sexually transmitted infections (not hiv or hepatitis) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a sexually transmitted infections (not hiv or hepatitis) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a sexually transmitted infections (not hiv or hepatitis) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.